Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin

A participant is eligible for the study if he/she fulfills all of the following inclusion criteria: 1. Healthy male and female participants ≥18 and ≤60 years, at the time of signing the informed consent. 2. Body mass index (BMI) ≥18.5 and ≤30.0 kg/m\^2. 3. Female participants of childbearing potential agree to undergo pregnancy tests resulting in negative results, non-lactating status, and agree to use accepted contraceptive method from at least 4 weeks prior to admission to the first study period until the end of the study, and if with a non-vasectomized nor infertile male partner, agree to use an appropriate method of contraception (i.e., abstinence, hormonal, intrauterine device, bilateral tubal occlusion). 4. No clinically relevant diseases captured in medical history. 5. No clinically relevant abnormalities on physical examination. 6. No clinically relevant abnormalities on vital signs. 7. No clinically relevant abnormalities on 12-lead electrocardiogram (ECG). 8. No clinically relevant abnormalities on clinical laboratory tests. 9. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤1.5 times the upper limit of normal range (ULN). 10. Estimated renal creatinine clearance (CrCl) above the lower limit of normal range, based on creatinine clearance calculation by the Cockcroft-Gault formula and normalized to an average body surface area of 1.73 m\^2. 11. Willingness to accept and comply with all study procedures and restrictions. 12. Non-smoker or ex-smoker (i.e., someone who abstained from using tobacco- or nicotine-containing products for at least 3 months prior to Screening). 13. Ability to comprehend and willingness to freely sign the informed consent. A participant is not eligible for the study at Screening if he/she fulfills any of the exclusion criteria as specified in the protocol.